While Exelixis Inc has underperformed by -2.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EXEL rose by 27.18%, with highs and lows ranging from $49.62 to $31.90, whereas the simple moving average jumped by 8.17% in the last 200 days.
On November 03, 2025, Guggenheim Downgraded Exelixis Inc (NASDAQ: EXEL) to Neutral. A report published by Leerink Partners on October 21, 2025, Upgraded its rating to ‘Outperform’ for EXEL. Barclays also rated EXEL shares as ‘Equal Weight’, setting a target price of $40 on the company’s shares in an initiating report dated September 19, 2025. Barclays Initiated an Equal Weight rating on September 17, 2025, and assigned a price target of $40. Goldman initiated its ‘Buy’ rating for EXEL, as published in its report on September 17, 2025. RBC Capital Mkts’s report from July 08, 2025 suggests a price prediction of $50 for EXEL shares, giving the stock a ‘Sector Perform’ rating. Stephens also rated the stock as ‘Overweight’.
Analysis of Exelixis Inc (EXEL)
Further, the quarter-over-quarter increase in sales is 10.79%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Exelixis Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of 30.56% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.68, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and EXEL is recording an average volume of 2.66M. On a monthly basis, the volatility of the stock is set at 3.81%, whereas on a weekly basis, it is put at 3.40%, with a gain of 3.80% over the past seven days. Furthermore, long-term investors anticipate a median target price of $45.00, showing growth from the present price of $42.35, which can serve as yet another indication of whether EXEL is worth investing in or should be passed over.
How Do You Analyze Exelixis Inc Shares?
A leading company in the Biotechnology sector, Exelixis Inc (EXEL) is based in the USA. When comparing Exelixis Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 17.83, there is a growth in quarterly earnings of 71.73%.
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.18%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 96.40% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
